GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Aug 20, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Aug 20, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction-in-own-shares, disclosure
TL;DR
GSK is buying back its own stock via Merrill Lynch.
AI Summary
GSK plc announced on August 20, 2025, that it has purchased a number of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing details a transaction in the company's own shares, with the specific number of shares purchased not fully detailed in the provided text snippet.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share repurchases, which is common for publicly traded companies.
Key Players & Entities
- GSK plc (company) — Registrant
- Merrill Lynch International (company) — Corporate stockbroker
- August 20, 2025 (date) — Transaction date
FAQ
What is the specific number of GSK ordinary shares purchased on August 20, 2025?
The provided text snippet indicates that GSK purchased ordinary shares on August 20, 2025, but the exact number of shares is not specified in the excerpt.
Who is acting as GSK's corporate stockbroker for this transaction?
Merrill Lynch International is acting as GSK's corporate stockbroker for the transaction.
What is the nominal value of GSK's ordinary shares mentioned in the filing?
The ordinary shares are described as having a nominal value of 31¼ pence each.
What type of report is this filing?
This filing is a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Does GSK file annual reports under Form 20-F or Form 40-F?
GSK indicates with an 'X' that it files annual reports under cover of Form 20-F.
Filing Stats: 2,917 words · 12 min read · ~10 pages · Grade level 3.5 · Accepted 2025-08-20 06:14:07
Filing Documents
- a9790v.htm (6-K) — 5924KB
- 0001654954-25-009835.txt ( ) — 5925KB
From the Filing
IN OWN SHARES a9790v   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of August 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .     Transaction in own shares   GSK plc (the " Company ") announces today   acting through its corporate stockbroker, Merrill Lynch International (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase:   19 August 2025   Aggregate number of ordinary shares of  31¼  pence each purchased:   211,358   Lowest price paid per share (GBp):   1,430.50p   Highest price paid per share (GBp):   1,452.50p   Volume-weighted average price paid per share (GBp):   1,442.73p     The purchased shares will be held as Treasury shares.   Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 24,575,644 ordinary shares.   Following the above purchase, the Company will hold 242,710,027 ordinary shares in treasury and have 4,072,681,707 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,072,681,707. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is   5.96 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.     Schedule of Purchases   Shares purchased:      GSK plc (ISIN: GB00BN7SWP63)   Date of purchases:     19 August 2025   Investment firm:           Merrill Lynch International     Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share) (GBp)   Lowest price paid (per ordinary share) (GBp)   Volume weighted average price paid (per ordinary share) (GBp)   London Stock Exchange (XLON)   211,358   1,452.50p   1,430.50p   1,442.73p   CBOE ( CHIX)   0   -   -   -   CBOE ( BATE)   0   -   -   -       Individual transactions:   Number ofShares   Price per Share (GBp)   Tradingvenue   Date oftransaction   Time oftransaction   Transaction reference number   11   1,435.50    XLON   19-Aug-2025   08:00:18   0XL06110000000005MNLLF   11   1,435.50    XLON   19-Aug-2025   08:00:18   0XL06700000000005MNLJL   11   1,435.50    XLON   19-Aug-2025   08:00:18   0XL06A00000000005MNLKE   11   1,435.50    XLON   19-Aug-2025   08:00:18   0XL06D00000000005MNLKK   12   1,435.50    XLON   19-Aug-2025   08:00:18   0XL06100000000005MNLBQ   12   1,435.50    XLON   19-Aug-2025   08:00:18   0XL06100000000005MNLBR   12   1,435.50    XLON   19-Aug-2025   08:00:18   0XL06110000000005MNLLG   12   1,435.50    XLON   19-Aug-2025   08:00:1